TY - JOUR
T1 - Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies
AU - Lorusso, Vito
AU - Cinieri, Saverio
AU - Giampaglia, Marianna
AU - Ciccarese, Mariangela
AU - Tinelli, Andrea
AU - Chiuri, Vincenzo
AU - Manca, Corrado
AU - Silvestris, Nicola
AU - Gasparini, Giampiero
AU - Colucci, Giuseppe
PY - 2010/6
Y1 - 2010/6
N2 - Vinorelbine (i.v.) plus capecitabine (oral) combination therapy is active in anthracycline/taxane pretreated patients with metastatic breast cancer. Availability of oral vinorelbine provides this combination in an all-oral formulation. Two consecutive phase II trials differing only in vinorelbine administration routes evaluated their respective activities and tolerabilities in this population. In the i.v. group (n = 38) disease control was 61% (37% PR, 24% SD), median TTP 6.8 months and median survival 11.3 months. In the oral group (n = 38) disease control was 77% (5.4% CR, 34% PR, 38% SD), median TTP 7 months and median survival 10 months. G3-G4 neutropenia was more common in the oral group (p <0.05); G2-G3 anaemia [5] and G3 thrombocytopenia [1] were observed only in the oral group. Although the comparison between the two regimens was not randomized, the results observed in these two consecutive phase II studies may suggest that oral and iv vinorelbine, in combination with capecitabine, can achieve similar responses in patients with metastatic breast cancer refractory to anthra-taxane combinations.
AB - Vinorelbine (i.v.) plus capecitabine (oral) combination therapy is active in anthracycline/taxane pretreated patients with metastatic breast cancer. Availability of oral vinorelbine provides this combination in an all-oral formulation. Two consecutive phase II trials differing only in vinorelbine administration routes evaluated their respective activities and tolerabilities in this population. In the i.v. group (n = 38) disease control was 61% (37% PR, 24% SD), median TTP 6.8 months and median survival 11.3 months. In the oral group (n = 38) disease control was 77% (5.4% CR, 34% PR, 38% SD), median TTP 7 months and median survival 10 months. G3-G4 neutropenia was more common in the oral group (p <0.05); G2-G3 anaemia [5] and G3 thrombocytopenia [1] were observed only in the oral group. Although the comparison between the two regimens was not randomized, the results observed in these two consecutive phase II studies may suggest that oral and iv vinorelbine, in combination with capecitabine, can achieve similar responses in patients with metastatic breast cancer refractory to anthra-taxane combinations.
KW - Administration
KW - Capecitabine
KW - Metastatic breast cancer
KW - Vinorelbine
UR - http://www.scopus.com/inward/record.url?scp=77953359063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953359063&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2010.01.015
DO - 10.1016/j.breast.2010.01.015
M3 - Article
C2 - 20167491
AN - SCOPUS:77953359063
VL - 19
SP - 214
EP - 218
JO - Breast
JF - Breast
SN - 0960-9776
IS - 3
ER -